

**SUMMARY OF CHANGES:**

**INSTRUMENT NOS. 37 to 52 OF 2018**

Statements of Principles (SOPs) Nos. 37 to 51 of 2018, and Determination No. 52 of 2018, were signed by the Chairperson of the Repatriation Medical Authority (the Authority) on 27 April 2018.

The Instruments have been lodged and registered with the Federal Register of Legislation, pursuant to section 15G of the *Legislation Act 2003* (Legislation Act). The day of commencement as specified in each of the Instruments is 28 May 2018. In accordance with the Legislation Act, the Office of Parliamentary Counsel must generally deliver a legislative instrument for laying before each House of the Parliament within six sitting days of that House after the instrument is registered with the instrument’s registered explanatory statement. The Instruments and the associated Explanatory Statements registered with the Federal Register of Legislation are available from: [http://www.legislation.gov.au](http://www.comlaw.gov.au).

Copies of each Instrument, the associated Explanatory Statement and a list of references relating to each Statement of Principles, are available in accordance with the *Veterans' Entitlements Act 1986* (the VEA), on written request from the RMA Secretariat.

The 'User Guide to the RMA Statements of Principles' explains the meaning and purpose of each section of the new SOP template which commenced in 2015. This document is available on the Authority's website <http://www.rma.gov.au>.

For further information contact:

The Registrar

Repatriation Medical Authority

GPO Box 1014

Brisbane Qld 4001

T +61 7 3815 9404

F +61 7 3815 9412

E info@rma.gov.au

4 May 2018

**SUMMARY OF CHANGES**

|  |  |  |  |
| --- | --- | --- | --- |
| **Instr. No.** | **Title** | **Date of Commencement** | **ICD-10-AM Codes** |
| **REVOCATIONS** | | | |
|  |  |  |  |
| 37 & 38/2018 | tension-type headache | 28/05/2018 | G44.2 |
|  |  |  |  |
| 39 & 40/2018 | herpes simplex | 28/05/2018 | B00 or A60 |
|  |  |  |  |
| 41 & 42/2018 | electrical injury | 28/05/2018 | T75.0 or T75.4 |
|  |  |  |  |
| 43 & 44/2018 | Cushing syndrome | 28/05/2018 | E24.0, E24.2, E24.3, E24.8 or E24.9 |
|  |  |  |  |
| **DETERMINATIONS** | | | |
|  |  |  |  |
| 45 & 46/2018 | central serous chorioretinopathy | 28/05/2018 | H35.7 |
|  |  |  |  |
| 47 & 48/2018 | temporomandibular disorder | 28/05/2018 | M26.60 |
|  |  |  |  |
| 49 & 50/2018 | mesenteric panniculitis | 28/05/2018 | K65.8 |
|  |  |  |  |
| **AMENDMENTS** | | | |
|  |  |  |  |
| 51/2018 | malignant neoplasm of the pancreas | 28/05/2018 | N/A |
|  |  |  |  |
| **REPEALING INSTRUMENT** | | | |
|  |  |  |  |
| 52/2018 | Veterans' Entitlements (Repeal of Expired Amendment Statements of Principles) Determination 2018 (No. 52 of 2018). | 28/05/2018 | N/A |
|  |  |  |  |

**Note**

* The investigation concerning 'Cushing's syndrome' has resulted in the determination of Statements of Principles concerning Cushing syndrome.
* The investigation concerning 'central serous retinopathy' has resulted in the determination of Statements of Principles concerning central serous chorioretinopathy.
* The investigation concerning 'temporomandibular joint dysfunction' has resulted in the determination of Statements of Principles concerning temporomandibular disorder.
* Following its focussed review in respect of exposure to DDT as a factor in malignant neoplasm of the pancreas, the Authority proposes to amend Statement of Principles No. 73 of 2013. The Authority does not propose to amend Statement of Principles No. 74 of 2013 and a Declaration is expected to appear in the Government Notices Gazette on 8 May 2018 advising of this outcome.
* The repealing instrument No. 52 of 2018 repeals 55 expired Amendment Statements of Principles that have no legal effect, to remove them from the Federal Register of Legislation.

| **SUMMARY OF CHANGES** | | |
| --- | --- | --- |
| 37 & 38/2018 | tension-type headache | These Instruments result from an investigation notified by the Authority in the Government Notices Gazette of 19 October 2016 concerning *tension-type headache* in accordance with section 196G of the VEA. The investigation involved an examination of the sound medical-scientific evidence now available to the Authority, including the sound medical-scientific evidence it has previously considered.  The contents of these Instruments are in similar terms as the revoked Instruments. Comparing these Instruments and the revoked Instruments, the differences include:  ***For RH SoP*** ***(Instrument No. 37/2018)***   * adopting the latest revised Instrument format, which commenced in 2015; * specifying a day of commencement for the Instrument in section 2; * revising the definition of 'tension-type headache' in subsection 7(2); * revising the reference to 'ICD-10-AM code' in subsection 7(4); * revising the factor in subsection 9(1) concerning 'taking a drug', for chronic tension-type headache in migraine and cluster headache sufferers only, for clinical onset only; * new factors in subsections 9(2) & 9(7) concerning 'a clinically significant disorder of mental health'; * new factors in subsections 9(3) & 9(8) concerning 'experiencing a category 2 stressor'; * new factors in subsections 9(4) & 9(9) concerning 'having insomnia'; * revising the factor in subsection 9(6) concerning 'taking a drug', for clinical worsening only; * new factors in subsections 9(5) & 9(11) concerning 'having concussion or moderate to severe traumatic brain injury'; * revising the factor in subsection 9(10) concerning 'treatment with a nitric oxide donor', for clinical worsening only; * new definitions of 'category 2 stressor', 'chronic tension-type headache', 'clinically significant disorder of mental health as specified', 'insomnia as specified', 'MRCA', 'nitric oxide donor', 'significant other', 'taking a drug as specified' and 'VEA' in Schedule 1 - Dictionary; * revising the definition of 'relevant service' in Schedule 1 - Dictionary; and * deleting the definitions of 'a drug or a combination of drugs, as specified in list 1', 'a drug or a combination of drugs, as specified in list 2' and 'frequent tension-type headache'.   ***For BoP SoP*** ***(Instrument No. 38/2018)***   * adopting the latest revised Instrument format, which commenced in 2015; * specifying a day of commencement for the Instrument in section 2; * revising the definition of 'tension-type headache' in subsection 7(2); * revising the reference to 'ICD-10-AM code' in subsection 7(4); * revising the factor in subsection 9(1) concerning 'taking a drug', for chronic tension-type headache in migraine and cluster headache sufferers only, for clinical onset only; * revising the factor in subsection 9(2) concerning 'taking a drug', for clinical worsening only; * revising the factor in subsection 9(3) concerning 'treatment with a nitric oxide donor', for clinical worsening only; * new definitions of 'chronic tension-type headache', 'MRCA', 'nitric oxide donor', 'taking a drug as specified' and 'VEA' in Schedule 1 - Dictionary; * revising the definition of 'relevant service' in Schedule 1 - Dictionary; and * deleting the definitions of 'a drug or a combination of drugs, as specified in list 1', 'a drug or a combination of drugs, as specified in list 2' and 'frequent tension-type headache'.   **The determining of these Instruments finalises the investigation in relation to *tension-type headache* as advertised in the Government Notices Gazette of 19 October 2016.** |
| 39 & 40/2018 | herpes simplex | These Instruments result from an investigation notified by the Authority in the Government Notices Gazette of 19 October 2016 concerning *herpes simplex* in accordance with section 196G of the VEA. The investigation involved an examination of the sound medical-scientific evidence now available to the Authority, including the sound medical-scientific evidence it has previously considered.  The contents of these Instruments are in similar terms as the revoked Instruments. Comparing these Instruments and the revoked Instruments, the differences include:  ***For RH SoP*** ***(Instrument No. 39/2018)***   * adopting the latest revised Instrument format, which commenced in 2015; * specifying a day of commencement for the Instrument in section 2; * revising the definition of 'herpes simplex' in subsection 7(2); * revising the reference to 'ICD-10-AM code' in subsection 7(4); * revising the factor in subsection 9(1) concerning 'being exposed to HSV-1 or HSV-2', for clinical onset only; * revising the factors in subsections 9(2) & 9(16) concerning 'a severe thermal burn'; * new factors in subsections 9(3) & 9(17) concerning 'a thermal or chemical burn'; * revising the factors in subsections 9(4) & 9(18) concerning 'being in an immunocompromised state'; * revising the factors in subsections 9(5) & 9(19) concerning 'surgery to nerve root ganglia'; * revising the factors in subsections 9(7) & 9(21) concerning 'being pregnant'; * revising the factors in subsections 9(8) & 9(22) concerning 'having surgery to the brain', for acute herpes simplex encephalitis and acute herpes simplex retinal necrosis only; * revising the factors in subsections 9(9)(a) & 9(23)(a) concerning 'having surgery to the face', for orofacial herpes simplex only; * new factors in subsections 9(9)(c) & 9(23)(c) concerning 'having a fever', for orofacial herpes simplex only; * new factors in subsections 9(10) & 9(24) concerning 'having a category 2 stressor', for orofacial herpes simplex or genital herpes simplex only; * new factors in subsections 9(11)(a) & 9(25)(a) concerning 'having cataract surgery', for herpes simplex of the cornea (herpes simplex keratitis) only; * new factor in subsection 9(11)(b) concerning 'having a corneal transplant', for herpes simplex of the cornea (herpes simplex keratitis) only, for clinical onset only; * new factors in subsections 9(11)(c) & 9(25)(b) concerning 'wearing contact lenses', for herpes simplex of the cornea (herpes simplex keratitis) only; * new factors in subsections 9(11)(d) & 9(25)(c) concerning 'being treated with topical prostaglandin eye solution', for herpes simplex of the cornea (herpes simplex keratitis) only; * new factors in subsections 9(12) & 9(26) concerning 'having periocular trauma', for acute herpes simplex retinal necrosis of the eye only; * new factors in subsections 9(13) & 9(27) concerning 'having atopic dermatitis', for herpes simplex of the eye only; * new factors in subsections 9(14)(a) & 9(28)(a) concerning 'having atopic dermatitis', for eczema herpeticum only; * new factors in subsections 9(14)(b) & 9(28)(b) concerning 'having a specified dermatosis', for eczema herpeticum only; * new factors in subsections 9(15)(a) & 9(29)(a) concerning 'having chapped lips', for herpes simplex of the lip only; * new factors in subsections 9(15)(b) & 9(29)(b) concerning 'playing a woodwind or brass musical instrument', for herpes simplex of the lip only; * new definitions of 'category 2 stressor', 'chapped lips', 'chronic renal failure', 'close to the site', 'eczema herpeticum', 'immunocompromised state as specified', 'immunosuppressive drug', 'MRCA', 'severe thermal burn', 'significant other', 'specified dermatosis', 'topical prostaglandin eye solution' and 'VEA' in Schedule 1 - Dictionary; * revising the definitions of 'being exposed to HSV-1 or HSV-2' and 'relevant service' in Schedule 1 - Dictionary; and * deleting the definitions of 'a significant thermal burn' and 'being in an immunosuppressed state'.   ***For BoP SoP*** ***(Instrument No. 40/2018)***   * adopting the latest revised Instrument format, which commenced in 2015; * specifying a day of commencement for the Instrument in section 2; * revising the definition of 'herpes simplex' in subsection 7(2); * revising the reference to 'ICD-10-AM code' in subsection 7(4); * revising the factor in subsection 9(1) concerning 'being exposed to HSV-1 or HSV-2', for clinical onset only; * revising the factors in subsections 9(2) & 9(13) concerning 'a severe thermal burn'; * new factors in subsections 9(3) & 9(14) concerning 'a thermal or chemical burn'; * revising the factors in subsections 9(4) & 9(15) concerning 'being in an immunocompromised state'; * revising the factors in subsections 9(5) & 9(16) concerning 'surgery to nerve root ganglia'; * revising the factors in subsections 9(7) & 9(18) concerning 'being at least 20 weeks pregnant'; * revising the factors in subsections 9(8) & 9(19) concerning 'having surgery to the brain', for acute herpes simplex encephalitis and acute herpes simplex retinal necrosis only; * revising the factors in subsections 9(9)(a) & 9(20)(a) concerning 'having surgery to the face', for orofacial herpes simplex only; * new factors in subsections 9(9)(c) & 9(20)(c) concerning 'having a fever', for orofacial herpes simplex only; * new factors in subsections 9(10)(a) & 9(21)(a) concerning 'having cataract surgery', for herpes simplex of the cornea (herpes simplex keratitis) only; * new factor in subsection 9(10)(b) concerning 'having a corneal transplant', for herpes simplex of the cornea (herpes simplex keratitis) only, for clinical onset only; * new factors in subsections 9(10)(c) & 9(21)(b) concerning 'wearing contact lenses', for herpes simplex of the cornea (herpes simplex keratitis) only; * new factors in subsections 9(11)(a) & 9(22)(a) concerning 'having atopic dermatitis', for eczema herpeticum only; * new factors in subsections 9(11)(b) & 9(22)(b) concerning 'having a psoriatic lesion', for eczema herpeticum only; * new factors in subsections 9(12)(a) & 9(23)(a) concerning 'having chapped lips', for herpes simplex of the lip only; * new factors in subsections 9(12)(b) & 9(23)(b) concerning 'playing a woodwind or brass musical instrument', for herpes simplex of the lip only; * new definitions of 'chapped lips', 'chronic renal failure', 'close to the site', 'eczema herpeticum', 'immunocompromised state as specified', 'immunosuppressive drug', 'MRCA', 'severe thermal burn' and 'VEA' in Schedule 1 - Dictionary; * revising the definitions of 'being exposed to HSV-1 or HSV-2' and 'relevant service' in Schedule 1 - Dictionary; and * deleting the definitions of 'a significant thermal burn' and 'being in an immunosuppressed state'.   **The determining of these Instruments finalises the investigation in relation to *herpes simplex* as advertised in the Government Notices Gazette of 19 October 2016.** |
| 41 & 42/2018 | electrical injury | These Instruments result from an investigation notified by the Authority in the Government Notices Gazette of 19 October 2016 concerning *electrical injury* in accordance with section 196G of the VEA. The investigation involved an examination of the sound medical-scientific evidence now available to the Authority, including the sound medical-scientific evidence it has previously considered.  The contents of these Instruments are in similar terms as the revoked Instruments. Comparing these Instruments and the revoked Instruments, the differences include:  ***For RH& BoP SoPs*** ***(Instrument Nos. 41 & 42/2018)***   * adopting the latest revised Instrument format, which commenced in 2015; * specifying a day of commencement for the Instrument in section 2; * revising the definition of 'electrical injury' in subsection 7(2); * revising the reference to 'ICD-10-AM code' in subsection 7(4); * new definitions of 'MRCA' and 'VEA' in Schedule 1 - Dictionary; and * revising the definition of 'relevant service' in Schedule 1 – Dictionary; and * deleting the definition of 'exposure to electrical current'.   **The determining of these Instruments finalises the investigation in relation to *electrical injury* as advertised in the Government Notices Gazette of 19 October 2016.** |
| 43 & 44/2018 | Cushing syndrome | These Instruments result from an investigation notified by the Authority in the Government Notices Gazette of 19 October 2016 concerning *Cushing's syndrome* in accordance with section 196G of the VEA. The investigation involved an examination of the sound medical-scientific evidence now available to the Authority, including the sound medical-scientific evidence it has previously considered.  The contents of these Instruments are in similar terms as the revoked Instruments. Comparing these Instruments and the revoked Instruments, the differences include:  ***For RH & BoP SoPs*** ***(Instrument Nos. 43 & 44/2018)***   * adopting the latest revised Instrument format, which commenced in 2015; * specifying a day of commencement for the Instrument in section 2; * changing the title of the Instrument to 'Cushing syndrome'; * revising the definition of 'Cushing syndrome' in subsection 7(2); * revising the reference to 'ICD-10-AM code' in subsection 7(4); * new factor in subsection 9(1) concerning 'having a specified condition'; * revising the factor in subsection 9(2) concerning 'having glucocorticoid therapy'; * revising the factor in subsection 9(3) concerning 'being treated with medroxyprogesterone acetate or megestrol acetate'; * deleting the factors concerning 'a neuroendocrine neoplasm', 'an adrenocorticotrophic hormone (ACTH) secreting neoplasm of the pituitary gland', 'micronodular or macronodular adrenal hyperplasia' and 'adrenal neoplasm', as they are subsumed by the factor in subsection 9(1) concerning 'having a specified condition'; * new definitions of 'adrenal neoplasm', 'glucocorticoid therapy as specified', 'MRCA, 'specified list of drugs' and 'VEA' in Schedule 1 - Dictionary; * revising the definitions of 'equivalent glucocorticoid therapy', 'equivalent inhaled glucocorticoid' and 'high or very high potency topical glucocorticoid' in Schedule 1 - Dictionary; and * deleting the definitions of 'a drug from the specified list' and 'having glucocorticoid therapy as specified'.   **The determining of these Instruments finalises the investigation in relation to *Cushing's syndrome* as advertised in the Government Notices Gazette of 19 October 2016.** |
| 45 & 46/2018 | central serous chorioretinopathy | **New Condition**  **The determining of these new Instruments finalises the investigation in relation to *central serous retinopathy* as advertised in the Government Notices Gazette of 11 July 2017.** |
| 47 & 48/2018 | temporomandibular disorder | **New Condition**  **The determining of these new Instruments finalises the investigation in relation to *temporomandibular joint dysfunction* as advertised in the Government Notices Gazette of 14 November 2017.** |
| 49 & 50/2018 | mesenteric panniculitis | **New Condition**  **The determining of these new Instruments finalises the investigation in relation to *mesenteric panniculitis* as advertised in the Government Notices Gazette of 14 November 2017.** |
| 51/2018 | malignant neoplasm of the pancreas | **Amendment**  This instrument amends Statement of Principles No. 73 of 2013 concerning ***malignant neoplasm of the pancreas*** by replacing the existing factor "(e)" in clause 6 concerning 'inhaling, ingesting or having cutaneous contact with DDT'.  **The determining of this Instrument finalises the investigation in relation to *malignant neoplasm of the pancreas* as advertised in the Government Notices Gazette of 9 January 2018.** |
| 52/2018 | Veterans' Entitlements (Repeal of Expired Amendment Statements of Principles) Determination 2018 (No. 52 of 2018) | **Determination**  **This instrument repeals the 55 expired Amendment Statements of Principles in *Schedule 1******- Expired Amendment Statements of Principles* attached. The effect of this repealing instrument is to remove expired legislative instruments that have no legal effect from the Federal Register of Legislation.** |
|  |  |  |

Schedule 1— Expired Amendment Statements of Principles

Expired Amendment Statements of Principles to be repealed:

| **Description** | **Federal Register of Legislation No.** |
| --- | --- |
| Amendment Statement of Principles concerning acute lymphoblastic leukaemia No. 37 of 2016 | F2016L00263 |
| Amendment Statement of Principles concerning acute myeloid leukaemia (Reasonable Hypothesis) (No. 33 of 2016) | F2016L00250 |
| Amendment Statement of Principles concerning acute myeloid leukaemia (Balance of Probabilities) (No. 34 of 2016) | F2016L00251 |
| Amendment Statement of Principles concerning anxiety disorder No. 99 of 2016 | F2016L01697 |
| Amendment Statement of Principles concerning anxiety disorder No. 100 of 2016 | F2016L01698 |
| Amendment Statement of Principles concerning aplastic anaemia No. 31 of 2016 | F2016L00260 |
| Amendment Statement of Principles concerning aplastic anaemia No. 32 of 2016 | F2016L00267 |
| Amendment Statement of Principles concerning chronic lymphocytic leukaemia/small lymphocytic lymphoma No. 38 of 2016 | F2016L00273 |
| Amendment Statement of Principles concerning chronic lymphoid leukaemia No. 28 of 2014 | F2014L00303 |
| Amendment Statement of Principles concerning chronic obstructive pulmonary disease No. 128 of 2015 | F2015L01687 |
| Amendment Statement of Principles concerning chronic obstructive pulmonary disease No. 129 of 2015 | F2015L01688 |
| Amendment Statement of Principles concerning depressive disorder (Reasonable Hypothesis) (No. 29 of 2016) | F2016L00257 |
| Amendment Statement of Principles concerning depressive disorder (Balance of Probabilities) (No. 30 of 2016) | F2016L00258 |
| Amendment Statement of Principles concerning diabetes mellitus No. 88 of 2014 | F2014L01150 |
| Amendment Statement of Principles concerning diabetes mellitus No. 89 of 2014 | F2014L01151 |
| Amendment Statement of Principles concerning diabetes mellitus No. 27 of 2016 | F2016L00276 |
| Amendment Statement of Principles concerning diabetes mellitus No. 28 of 2016 | F2016L00278 |
| Amendment Statement of Principles concerning fibrosing interstitial lung disease No. 59 of 2010 | F2010L01672 |
| Amendment Statement of Principles concerning fibrosing interstitial lung disease No. 60 of 2010 | F2010L01673 |
| Amendment Statement of Principles concerning fibrosing interstitial lung disease No. 79 of 2011 | F2011L00730 |
| Amendment Statement of Principles concerning fibrosing interstitial lung disease No. 80 of 2011 | F2011L00732 |
| Amendment Statement of Principles concerning fibrosing interstitial lung disease No. 66 of 2012 | F2012L01811 |
| Amendment Statement of Principles concerning fibrosing interstitial lung disease No. 67 of 2012 | F2012L01812 |
| Amendment Statement of Principles concerning ischaemic heart disease No. 33 of 2014 | F2014L00302 |
| Amendment Statement of Principles concerning lipoma (Balance of Probabilities) (No. 115 of 2015) | F2015L01388 |
| Amendment Statement of Principles concerning lipoma (Reasonable Hypothesis) (No. 114 of 2015) | F2015L01387 |
| Amendment Statement of Principles concerning lumbar spondylosis No. 69 of 2013 | F2013L01657 |
| Amendment Statement of Principles concerning lumbar spondylosis No. 70 of 2013 | F2013L01658 |
| Amendment Statement of Principles concerning malignant neoplasm of the oesophagus (Reasonable Hypothesis) (No. 21 of 2017) | F2017L00018 |
| Amendment Statement of Principles concerning malignant neoplasm of the ovary (Balance of Probabilities) (No. 36 of 2018) | F2018L00184 |
| Amendment Statement of Principles concerning malignant neoplasm of the ovary (Reasonable Hypothesis) (No. 35 of 2018) | F2018L00185 |
| Amendment Statement of Principles concerning malignant neoplasm of the prostate No. 19 of 2017 | F2017L00017 |
| Amendment Statement of Principles concerning malignant neoplasm of the prostate No. 20 of 2017 | F2017L00019 |
| Amendment Statement of Principles concerning motor neurone disease No. 53 of 2009 | F2009L02423 |
| Amendment Statement of Principles concerning myelodysplastic syndrome (Reasonable Hypothesis) (No. 35 of 2016) | F2016L00252 |
| Amendment Statement of Principles concerning myelodysplastic syndrome (Balance of Probabilities) (No. 36 of 2016) | F2016L00253 |
| Amendment Statement of Principles concerning myeloma No. 39 of 2016 | F2016L00277 |
| Amendment Statement of Principles concerning myeloma No. 72 of 2014 | F2014L00936 |
| Amendment Statement of Principles concerning myeloma No. 73 of 2014 | F2014L00935 |
| Amendment Statement of Principles concerning non-Hodgkin's lymphoma No. 57 of 2014 | F2014L00485 |
| Amendment Statement of Principles concerning non-Hodgkin's lymphoma No. 86 of 2014 | F2014L01148 |
| Amendment Statement of Principles concerning non-Hodgkin's lymphoma No. 87 of 2014 | F2014L01149 |
| Amendment Statement of Principles concerning non-Hodgkin's lymphoma No. 93 of 2015 | F2015L00933 |
| Amendment Statement of Principles concerning non-Hodgkin's lymphoma No. 40 of 2016 | F2016L00280 |
| Amendment Statement of Principles concerning otitic barotrauma No. 15 of 2017 | F2017L00009 |
| Amendment Statement of Principles concerning otitic barotrauma No. 16 of 2017 | F2017L00011 |
| Amendment Statement of Principles concerning panic disorder (No. 101 of 2016) | F2016L01681 |
| Amendment Statement of Principles concerning panic disorder (No. 102 of 2016) | F2016L01668 |
| Amendment Statement of Principles concerning posttraumatic stress disorder No. 19 of 2014 | F2014L00066 |
| Amendment Statement of Principles concerning sinus barotrauma No. 17 of 2017 | F2017L00013 |
| Amendment Statement of Principles concerning sinus barotrauma No. 18 of 2017 | F2017L00014 |
| Amendment Statement of Principles concerning suicide and attempted suicide (Reasonable Hypothesis) (No. 26 of 2017) | F2017L00174 |
| Amendment Statement of Principles concerning suicide and attempted suicide (Balance of Probabilities) (No. 27 of 2017) | F2017L00175 |
| Amendment Statement of Principles concerning suicide and attempted suicide (Reasonable Hypothesis) (No. 33 of 2018) | F2018L00207 |
| Amendment Statement of Principles concerning suicide and attempted suicide (Balance of Probabilities) (No. 34 of 2018) | F2018L00209 |

.